standard corticosteroid treatment
Phase 3
standard corticosteroid treatment is one of 27 therapeutic programs targeting Nephrotic Syndrome. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
30 competitors in Nephrotic Syndrome
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Cellcept
RocheApproved
Farxiga
AstraZenecaApproved
Neoral
NovartisApproved
Lovenox
SanofiApproved
Rayos
RRoxane Laboratories
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Aldactone
PfizerApproved
Thalitone
Jazz PharmaceuticalsApproved
Decadron
AAspen Global Incorporated
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]